尼拉帕利维持治疗改善复发性卵巢癌无症无毒时间:ENGOT-OV16/NOVA试验TWiST分析
该分析基于ENGOT-OV16/NOVA III期试验中553例复发性卵巢癌患者,采用参数生存模型估算尼拉帕利与常规监测的平均PFS和毒性时间,进而计算TWiST。结果显示,在gBRCAmut和非gBRCAmut队列中,尼拉帕利较常规监测分别带来平均TWiST获益2.95年和1.34年,且敏感性分析结果一致。
要点
- gBRCAmut队列尼拉帕利较常规监测平均TWiST获益2.95年。
- 非gBRCAmut队列尼拉帕利较常规监测平均TWiST获益1.34年。
- TWiST获益在5年、10年、15年时间 horizon 等敏感性分析中一致。
核心结论
- 尼拉帕利维持治疗较常规监测显著增加复发性卵巢癌患者的平均无症无毒时间(TWiST)。
研究设计与样本
- 基于III期ENGOT-OV16/NOVA试验中553例复发性卵巢癌患者,按gBRCAmut状态分队列,拟合参数生存分布估算平均PFS。
- 毒性时间基于≥2级症状性疲劳、恶心、呕吐不良事件Kaplan-Meier曲线下面积估算,TWiST为平均PFS与毒性时间之差。
主要发现
- gBRCAmut队列尼拉帕利较常规监测平均PFS获益3.23年,平均毒性时间0.28年,平均TWiST获益2.95年。
- 非gBRCAmut队列尼拉帕利较常规监测平均PFS获益1.44年,平均毒性时间0.10年,平均TWiST获益1.34年。
- gBRCAmut和非gBRCAmut队列尼拉帕利较常规监测平均TWiST分别增加超过四倍和两倍。
临床怎么用
- 可将TWiST作为尼拉帕利维持治疗获益的补充评估指标,结合PFS和毒性综合考量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study estimated time without symptoms or toxicity (TWiST) with niraparib compared with routine surveillance (RS) in the maintenance treatment of patients with recurrent ovarian cancer. PATIENTS AND METHODS: Mean progression-free survival (PFS) was estimated for niraparib and RS by fitting parametric survival distributions to Kaplan-Meier data for 553 patients with recurrent ovarian cancer who were enrolled in the phase III ENGOT-OV16/NOVA trial. Patients were categorized according to the presence or absence of a germline BRCA mutation-gBRCAmut and non-gBRCAmut cohorts. Mean time with toxicity was estimated based on the area under the Kaplan-Meier curve for symptomatic grade 2 or greater fatigue, nausea, and vomiting adverse events (AEs). Time with toxicity was the number of days a patient experienced an AE post-random assignment and before disease progression. TWiST was estimated as the difference between mean PFS and time with toxicity. Uncertainty was explored using alternative PFS estimates and considering all symptomatic grade 2 or greater AEs. RESULTS: In the gBRCAmut and non-gBRCAmut cohorts, niraparib treatment resulted in a mean PFS benefit of 3.23 years and 1.44 years, respectively, and a mean time with toxicity of 0.28 years and 0.10 years, respectively, compared with RS. Hence, niraparib treatment resulted in a mean TWiST benefit of 2.95 years and 1.34 years, respectively, compared with RS, which is equivalent to more than four-fold and two-fold increases in mean TWiST between niraparib and RS in the gBRCAmut and non-gBRCAmut cohorts, respectively. This TWiST benefit was consistent across all sensitivity analyses, including modeling PFS over 5-, 10-, and 15-year time horizons. CONCLUSION: Patients who were treated with niraparib compared with RS experienced increased mean TWiST. Thus, patients who were treated with niraparib in the ENGOT-OV16/NOVA trial experienced more time without symptoms or symptomatic toxicities compared with control.
引用
- Matulonis UA, Walder L, Nøttrup TJ, et al. Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial. J Clin Oncol. 2019. PMID: 31518175. doi:10.1200/JCO.19.00917
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。